Zdrowie i gospodarka · 14/04/2009
FDA Clears ZOMETA for Approval After Safety Review
The FDA has determined that ZOMETA, a zoledronic acid injection, was not withdrawn from sale due to safety concerns, paving the way for approval of abbreviated new drug applications for the 4-mg base/vial version.
Source: Federal Register — Food and Drug AdministrationOpen original release →